ABBOTT LABORATORIES — Board/Management Information 2017

Feb 17, 2017

8-K 1 a17-4560_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D. C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of the*

*Securities Exchange Act of 1934*

*February 16, 2017*

Date of Report (Date of earliest event reported)

*ABBOTT LABORATORIES*

(Exact name of registrant as specified in its charter)

Illinois	1-2189	36-0698440
(State or other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

*100 Abbott Park Road*

*Abbott Park, Illinois 60064-6400*

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\C902312\17-4560-1\task8285255\4560-1-ba.htm',USER='C902312',CD='Feb 18 01:08 2017'

*Item 5.02 — Election of Directors*

On February 16, 2017, Daniel J. Starks was named to the Abbott Board of Directors, effective immediately.

*Item 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year*

On February 16, 2017, Abbott Laboratories’ Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of twelve persons, effective as of February 16, 2017. Abbott’s by-laws previously provided that the Board of Directors consisted of eleven persons.

*Item 9.01 Financial Statements and Exhibits*

Exhibit No.	Exhibit
3.1	By-Laws of Abbott Laboratories, as amended and restated effective February 16, 2017.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\C902312\17-4560-1\task8285255\4560-1-ba.htm',USER='C902312',CD='Feb 18 01:08 2017'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Brian B. Yoor
Brian B. Yoor
Senior Vice President, Finance
and Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\C902312\17-4560-1\task8285255\4560-1-ba.htm',USER='C902312',CD='Feb 18 01:08 2017'

*EXHIBIT INDEX*

Exhibit No.	Exhibit
3.1	By-Laws of Abbott Laboratories, as amended and restated effective February 16, 2017.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\C902312\17-4560-1\task8285255\4560-1-ba.htm',USER='C902312',CD='Feb 18 01:08 2017'